TELA Bio, Inc.
NASDAQ:TELAMedical - Devices
+$0.09 today
- Market cap
- $51.00M
- Beta
- 1.36
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.72
Volume 0.22M
Average 0.17M
TELA Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
TELA Bio, Inc.NASDAQ: TELA
Net Margin · Q2 FY2026 · quarter ended Jun 2026
Net margin narrows to -58.4%
Net margin was -58.4% in Q2 FY2026, down 9.2 pp from a year earlier. On a trailing-twelve-month basis it was -51.5%, up 2.6 pp year over year. Over 3 fiscal years it widened by 58.6 pp.
Context
- Net margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 4 analysts of -40.0% for the fiscal year ending Dec 2026, up from -48.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -58.4%+6.0 pp QoQ
- Last fiscal yearDec 2025
- -48.4%+6.2 pp YoY
- LTMJun 2026
- -51.5%+2.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.2 pp | -3.0 pp | +6.2 pp |
| 1 year | +6.2 pp | +8.4 pp | +2.2 pp |
| 3 years | +58.6 pp | +32.0 pp | -26.5 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -48.4%
- Year-over-year change
- +6.2pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -48.4% | +6.2pp |
| FY2024 | 2024-12-31 | -54.6% | +25.2pp |
| FY2023 | 2023-12-31 | -79.8% | +27.1pp |
| FY2022 | 2022-12-31 | -106.9% | +6.0pp |
| FY2021 | 2021-12-31 | -112.9% | — |
Net Margin vs competitors
How TELA compares with its peers on the latest reported figures
- TELA's LTM Jun 2026 net margin of -51.5% is the 2nd highest of the 7 companies compared; the peer median is -462.6%.
- Its year-over-year change of +2.6 pp is the 3rd highest of 6, against a peer median of -39.1 pp.
- Over three fiscal years its change of +58.6 pp compares with a peer median of -27.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -34.5% | -39.1 pp | -82.5 pp | |
| LTM Jun 2026 | -51.5% | +2.6 pp | +58.6 pp | |
| LTM Mar 2026 | -59.6% | +448.2 pp | +4161.0 pp | |
MDAISpectral AI, Inc. | LTM Mar 2026 | -85.6% | -54.8 pp | -27.1 pp |
| LTM Mar 2026 | -839.7% | +14705.1 pp | — | |
| LTM Mar 2026 | -1070.3% | — | — | |
| LTM Mar 2026 | -18297.5% | -30712.4 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding TELA) | -462.6% | -39.1 pp | -27.1 pp | |
Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 29.46M | 41.42M | 58.45M | 69.3M | 80.28M |
| Cost of Revenue | 10.65M | 14.37M | 18.34M | 22.81M | 25.93M |
| Gross Profit | 18.81M | 27.04M | 40.11M | 46.49M | 54.34M |
| Gross Margin | 63.9% | 65.3% | 68.6% | 67.1% | 67.7% |
| Research & Development | 6.74M | 8.94M | 9.62M | 8.81M | 9.22M |
| Selling, General & Admin | 41.52M | 57.11M | 74.57M | 79.37M | 78.88M |
| Operating Expenses | 48.26M | 66.05M | 84.19M | 80.6M | 88.1M |
| Depreciation & Amortization | 535K | 1.19M | 808K | 1.01M | 1.01M |
| EBITDA | (29.14M) | (39.06M) | (40.63M) | (31.68M) | (32.35M) |
| EBITDA Margin | -98.9% | -94.3% | -69.5% | -45.7% | -40.3% |
| Operating Income | (29.45M) | (39.01M) | (44.08M) | (34.12M) | (33.76M) |
| Operating Margin | -100.0% | -94.2% | -75.4% | -49.2% | -42.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.6M | 4.05M | 5.22M | 5.29M | 5.25M |
| Other Income / Expenses | (3.83M) | (5.29M) | (2.59M) | (3.87M) | (4.85M) |
| Income Before Tax | (33.28M) | (44.3M) | (46.66M) | (37.99M) | (38.6M) |
| Pre-Tax Margin | -112.9% | -106.9% | -79.8% | -54.8% | -48.1% |
| Income Tax Expense | 0 | 0 | 0 | (144K) | 230K |
| Net Income | (33.28M) | (44.3M) | (46.66M) | (37.84M) | (38.83M) |
| Net Margin | -112.9% | -106.9% | -79.8% | -54.6% | -48.4% |
| EPS (Basic) | (2.30) | (2.73) | (2.04) | (1.33) | (0.83) |
| EPS (Diluted) | (2.30) | (2.73) | (2.04) | (1.33) | (0.83) |
| Weighted Avg Shares | 14.47M | 16.27M | 22.87M | 28.53M | 46.95M |
| Weighted Avg Shares (Diluted) | 14.47M | 16.27M | 22.87M | 28.53M | 46.95M |
TELA Bio, Inc.
NASDAQ:TELA
Intrinsic Alpha fair value
Locked
Current Price
$1.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.